164 related articles for article (PubMed ID: 20177411)
1. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody.
Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC
Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411
[TBL] [Abstract][Full Text] [Related]
2. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
[TBL] [Abstract][Full Text] [Related]
3. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate.
Zeng W; Tan AC; Horrocks K; Jackson DC
Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002
[TBL] [Abstract][Full Text] [Related]
4. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
5. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein.
Andersson AM; Håkansson KO; Jensen BA; Christensen D; Andersen P; Thomsen AR; Christensen JP
PLoS One; 2012; 7(10):e46395. PubMed ID: 23049700
[TBL] [Abstract][Full Text] [Related]
6. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
7. Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide.
Zykova AA; Blokhina EA; Kotlyarov RY; Stepanova LA; Tsybalova LM; Kuprianov VV; Ravin NV
Viruses; 2020 Oct; 12(10):. PubMed ID: 33036278
[TBL] [Abstract][Full Text] [Related]
8. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
10. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
11. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.
Deng L; Ibañez LI; Van den Bossche V; Roose K; Youssef SA; de Bruin A; Fiers W; Saelens X
PLoS One; 2015; 10(5):e0126650. PubMed ID: 25973787
[TBL] [Abstract][Full Text] [Related]
12. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
[TBL] [Abstract][Full Text] [Related]
13. The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure.
Kitikoon P; Strait EL; Thacker EL
Vet Microbiol; 2008 Jan; 126(1-3):51-62. PubMed ID: 17719187
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
Kaminaka K; Matsuda J; Nozaki C
Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
[TBL] [Abstract][Full Text] [Related]
15. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
[TBL] [Abstract][Full Text] [Related]
16. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
[TBL] [Abstract][Full Text] [Related]
17. Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.
Lee YN; Kim MC; Lee YT; Hwang HS; Lee J; Kim C; Kang SM
PLoS One; 2015; 10(9):e0137822. PubMed ID: 26366729
[TBL] [Abstract][Full Text] [Related]
18. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
19. Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
Kolpe A; Schepens B; Ye L; Staeheli P; Saelens X
Antiviral Res; 2018 Oct; 158():244-254. PubMed ID: 30179634
[TBL] [Abstract][Full Text] [Related]
20. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
